ClinConnect ClinConnect Logo
Search / Trial NCT06887348

A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

Launched by REPLIMUNE INC. · Mar 14, 2025

Trial Information

Current as of April 26, 2025

Not yet recruiting

Keywords

Advanced Solid Tumors Immunotherapy Immuno Oncology Oncolytic Virus Oncolytic Immuno Gene Therapy Hepatocellular Carcinoma Cutaneous Melanoma Anti Pd1 Failed Non Melanoma Skin Cancer Melanoma (Skin)

ClinConnect Summary

This clinical trial is designed to look at the long-term safety of certain treatments called RPx products in patients who have previously received at least one dose of these treatments for conditions like melanoma, advanced solid tumors, or liver cancer. The study will follow participants for five years to check for any potential delayed side effects from the RPx products. It's important to note that this is an observational study, meaning researchers will be monitoring patients without giving them new treatments during this time.

To be eligible for the study, patients must have completed or withdrawn from a related study where they received RPx treatments and must give their consent to participate. The trial is open to all adults aged 65 and older. Participants can expect regular follow-ups over the five years to ensure their health is monitored and to gather important information about their experiences after treatment. This study aims to help understand the long-term effects of these cancer treatments and ensure patient safety.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients are eligible for inclusion in the study only if they meet all of the following criteria:
  • 1. Patient has received at least 1 dose of an RPx product and has completed or discontinued participation in the parent study.
  • 2. Patient or patient's legal guardian has provided signed informed consent (or assent) as , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Exclusion Criteria:
  • Patients are excluded from the study if the following criterion applies:
  • 1. Cannot comply with the requirements of the study.

About Replimune Inc.

Replimune Inc. is an innovative biotechnology company focused on developing next-generation oncolytic immunotherapies for the treatment of various cancers. Leveraging its proprietary platform, Replimune aims to harness the power of the immune system by using genetically engineered viruses that selectively target and destroy cancer cells while stimulating systemic immune responses. With a commitment to advancing science and improving patient outcomes, Replimune is at the forefront of transforming cancer treatment through its robust pipeline of clinical trials and collaborations, working to bring novel therapies to patients in need.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported